Key clinical point: Older age, relapsed/refractory (r/r) disease in lymphoma patients tied to an increased death rate from COVID-19.
Major finding: Patients younger than age 70 years, without r/r lymphoma had an 88% 30-day overall survival, comparable to the general population.
Study details: Retrospective database of all 89 adult patients with lymphoma who were hospitalized for COVID-19.
Disclosures: The study was unsponsored. Several of the authors reported financial relationships with a number of biotechnology and pharmaceutical companies.
Lamurea S et al. EClinicalMedicine. 2020 Oct 12. doi: 10.1016/j.eclinm.2020.100549.